Skip to main content

Table 1 Eligibility criteria

From: Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review

 

Direct evidence

Linked evidence

intervention studies

diagnostic accuracy study

intervention studies

Population

• RhD-negative pregnant women without sensitization

• RhD-negative pregnant women without sensitization

• RhD-negative pregnant women without sensitization

Study intervention

• non-invasive prenatal RhD-testing of the fetus and omission of antenatal anti-D prophylaxis in the case of an RhD- negative fetus

• non-invasive prenatal RhD-testing of the fetus

• administration of anti-D prophylaxis

Control intervention

• anti-D prophylaxis for all RhD-negative pregnant women

• postnatal RhD-testing of the newborn

• no antenatal administration of anti-D prophylaxis

   

Benefits

Harms

Patient-relevant outcomes/diagnostic accuracy measures

• mortality

• test accuracy (sensitivity, specificity, false-negative rate, false-positive rate)

• mortality

• mortality

• HDFN (surrogate outcome: sensitization)

• HDFN (surrogate outcome: sensitization)

• adverse events

• adverse events

• health-related quality of life

• health-related quality of life

• health-related quality of life

Study type

• RCTs

• prospective cohort studies

• RCTs

• RCTs

• prospective, non-randomized controlled intervention studies

• prospective, non-randomized controlled intervention studies

• prospective, non-randomized controlled intervention studies

• cohort studies (also retrospective or with historical controls)

  1. HDFN: hemolytic disease of the fetus and newborn